Target Name: GYG2
NCBI ID: G8908
Review Report on GYG2 Target / Biomarker Content of Review Report on GYG2 Target / Biomarker
GYG2
Other Name(s): Gycogenin glucosyltransferase | Glycogenin-2 | UDP-glucose:glycogenin glucosyltransferase | glycogenin glucosyltransferase | Glycogenin-2 (isoform b) | glycogenin 2 | GYG2 variant 2 | Glycogenin 2, transcript variant 1 | Glycogenin-2 (isoform a) | Priming glucosyltransferase | GYG2 variant 1 | Glycogenin | GN-2 | GN2 | GLYG2_HUMAN | Glycogenin 2, transcript variant 2

GYG2: A Potential Drug Target and Biomarker for Glycogenin Glucosyltransferase

Glycogenin glucosyltransferase (GYG2) is a protein that plays a crucial role in the metabolism of glycogen, which is a complex carbohydrate that is stored in the liver for energy reserve. GYG2 is a key enzyme in the glycogen biosynthesis pathway, and its dysfunction has been implicated in a number of diseases, including obesity, type 2 diabetes, and cardiovascular disease. As a result, GYG2 has emerged as a promising drug target and biomarker for a variety of diseases.

The discovery and characterization of GYG2

GYG2 was first identified as a gene encoding a protein with homology to the heat shock protein HSP70. HSP70 is a well-known protein that plays a critical role in stress response and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and cardiomyopathy. The search for a related protein led to the identification of GYG2, which has also been shown to have homology to HSP70 and other proteins involved in stress response and metabolism.

GYG2 is a key enzyme in the glycogen biosynthesis pathway

Glycogen is a complex carbohydrate that is stored in the liver for energy reserve. It is composed of two main components: alpha-glucopyranoside and beta-glucopyranoside. The alpha-glucopyranoside is the main structural component, while the beta-glucopyranoside is a modified form of alpha-glucopyranoside that has a glucose unit added to the 2-OH group. The biosynthesis of glycogen occurs through a series of enzyme-catalyzed reaction steps, including the activity of GYG2.

GYG2 is involved in the transfer of the first glucose unit from the diet to the alpha-glucopyranoside during the first step of biosynthesis, known as the 1,4-beta-glucosylation step. In this step, GYG2 uses a specific active site, which is located on the alpha-glucopyranoside, to transfer the first glucose unit from the diet to the alpha-glucopyranoside. The 1,4-beta-glucosylation step is critical for the efficiency of glycogen biosynthesis, and GYG2 is a key enzyme that promotes this step.

GYG2 is also involved in the transfer of the second glucose unit from the diet to the alpha-glucopyranoside during the second step of biosynthesis, known as the 1,6-beta-glucosylation step. In this step, GYG2 uses a different active site, which is located on the alpha-glucopyranoside, to transfer the second glucose unit from the diet to the alpha-glucopyranoside. The 1,6-beta-glucosylation step is also critical for the efficiency of glycogen biosynthesis, and GYG2 is a key enzyme that promotes this step.

GYG2 is a potential drug target

GYG2 has been shown to play a role in a number of diseases, including obesity, type 2 diabetes, and cardiovascular disease. Its dysfunction in these diseases has been associated with the misfolding and localization of GYG2 to the endoplasmic reticulum, where it can interact with and modulate the activities of other proteins involved in metabolism and energy homeostasis.

GYG2 has also been shown to be involved in the regulation of

Protein Name: Glycogenin 2

Functions: Self-glucosylates, via an inter-subunit mechanism, to form an oligosaccharide primer that serves as substrate for glycogen synthase

The "GYG2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GYG2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2 | H2BP3 | H2BW1 | H2BW2 | H2BW4P | H3-3A | H3-3B | H3-4 | H3-5 | H3-7 | H3C1 | H3C10 | H3C11 | H3C12 | H3C13 | H3C14 | H3C15 | H3C2 | H3C3 | H3C4 | H3C6 | H3C7 | H3C8 | H3P16 | H3P36